Polyphenol & Plant Antioxidants: Resveratrol, Quercetin & Green Tea EGCG Data

Overview #

Polyphenols are not fragile by reputation — they’re fragile by chemistry. Resveratrol, quercetin, and EGCG each degrade through distinct mechanisms, and the formulation decisions that protect one can actively destabilize another. We’ve run enough failed co-formulation batches to stop treating these three as interchangeable “antioxidant actives.” They aren’t. The stability windows are narrow, the incompatibilities are real, and the packaging decisions matter more than most brand briefs acknowledge.

Degradation Mechanisms and Numeric Thresholds #

Resveratrol’s primary failure mode is photoisomerization. The trans-resveratrol form — the biologically active one — converts to cis-resveratrol under UV exposure, and that conversion is essentially irreversible in a finished product. In our stability chamber, we’ve seen trans-resveratrol drop below 80% assay within 6 weeks at 40°C/75% RH in clear glass packaging. Switch to amber glass or opaque airless, and the same formula holds above 90% at 12 weeks. That’s not a minor packaging footnote. That’s the difference between a product that works and one that doesn’t.

Quercetin degrades primarily through oxidation, and the rate accelerates sharply above pH 7.0. We keep quercetin formulations between pH 4.5 and 6.0. Above that range, the catechol ring opens and you get brown discoloration — not a stability artifact, actual degradation. The color shift is visible to consumers by week 4 in accelerated testing. Below pH 4.0, solubility becomes the problem. Quercetin’s aqueous solubility is already poor (roughly 0.01 mg/mL at room temperature), and acidic conditions don’t help. Most of our quercetin work ends up in anhydrous or low-water formats for exactly this reason.

EGCG is the most oxidation-sensitive of the three. It auto-oxidizes in the presence of dissolved oxygen, and the reaction is catalyzed by trace metals — iron and copper especially. We require suppliers to certify iron content below 1 ppm in any water phase destined for EGCG formulations. Even then, we use chelating agents (EDTA at 0.1–0.2% or phytic acid for clean-label briefs) as standard practice. At 45°C, unprotected EGCG in an aqueous serum can lose 40% potency in under 4 weeks. That’s not a worst-case scenario. That’s what we see routinely without proper oxygen management.

Temperature thresholds across all three: keep processing below 40°C. Resveratrol and EGCG are both heat-sensitive enough that standard hot-process emulsification at 70–75°C causes measurable degradation before the batch even cools. We add all three post-cool, below 40°C, every time.

Incompatible Combinations and pH Conflicts #

This is usually where projects go sideways.

The most common brief we receive: “We want resveratrol, vitamin C, and EGCG in one serum.” Understandable from a marketing angle. Difficult from a chemistry one. L-ascorbic acid requires pH 2.5–3.5 for stability. Quercetin degrades above pH 6.0 but needs at least pH 4.5 for reasonable stability. EGCG is most stable between pH 4.0 and 6.0. Resveratrol is relatively pH-tolerant but oxidizes in the presence of ascorbic acid’s degradation byproducts. You cannot satisfy all four stability windows simultaneously in a single aqueous phase.

Our standard response to that brief: pick two. Or use encapsulation to isolate the pH-sensitive actives. Encapsulation technology adds cost and complexity, but it’s the only technically sound path to a stable multi-antioxidant formula at meaningful concentrations.

Niacinamide is another common co-formulation request. At elevated temperatures and low pH, niacinamide and ascorbic acid form nicotinic acid — a known flushing agent. That reaction is well-documented. Less discussed: niacinamide at concentrations above 5% can complex with EGCG and reduce its bioavailability. We’re still not fully convinced the clinical significance is large, but we’ve seen enough in-vitro binding data to flag it on every brief that combines the two.

Iron-containing botanical extracts — certain plant waters, some fermented ingredients — are incompatible with EGCG for the metal-catalysis reason above. We rejected one supplier’s fermented rice water ingredient specifically because the iron content was 3.2 ppm, which pushed EGCG degradation past acceptable limits in our 8-week accelerated test.

Alkaline actives (bakuchiol at high load, some peptide complexes buffered above pH 7) are incompatible with quercetin. We almost always push back on briefs that combine these without a clear pH strategy. See also our notes on vitamin C and antioxidant systems for the broader pH conflict landscape across antioxidant actives.

Stability Parameters: What the Numbers Actually Look Like #

The table below reflects our internal pass/fail thresholds based on ICH-aligned accelerated stability protocols (ICH Stability Guidelines). These are working parameters from our lab, not theoretical ranges.

One thing this table doesn’t capture: the interaction effects. A formula that passes individual active stability can still fail when all three are combined, because the degradation products of one active can catalyze degradation of another. We run combination stability separately from single-active stability as standard protocol.

For regulatory reference, all three actives fall under general cosmetic ingredient provisions in the EU Cosmetics Regulation 1223/2009. There are no specific concentration restrictions, but the SCCS has published opinions on polyphenol safety that inform our safety assessment process — SCCS Scientific Opinion is worth reviewing if you’re targeting EU markets. For US market, FDA Cosmetics Guidelines apply the standard cosmetic ingredient framework with no specific polyphenol restrictions at current use levels.

The Clinical Picture — and Where We’re Skeptical #

The strongest clinical data in this category belongs to EGCG. A double-blind, randomized controlled trial (n=60, 12 weeks, twice-daily application of a 2% EGCG serum) demonstrated a 34% reduction in UV-induced erythema score versus vehicle control, alongside a statistically significant improvement in skin elasticity measured by cutometry. That’s a well-designed study and the results are reproducible in our own consumer perception testing — when the formula is stable. The caveat is always stability. A 2% EGCG serum that’s lost 40% potency by the time it reaches the consumer is effectively a 1.2% formula, and the clinical data doesn’t support that concentration.

Resveratrol’s clinical evidence is thinner than the marketing suggests. Most published data is in vitro or in vivo at concentrations that aren’t achievable in a stable topical formula. Honestly, we’re not convinced the topical bioavailability story is fully resolved. The molecule is large, the skin penetration data is inconsistent across studies, and the trans/cis stability issue means the delivered dose is often unknown. We still formulate it — brand demand is real and the safety profile is good — but we’re careful about what claims we support.

Quercetin’s topical data is the thinnest of the three. Most of the interesting work is oral supplementation research, which doesn’t translate directly to topical application. In our own formulation work, quercetin earns its place primarily as a synergistic antioxidant and anti-inflammatory support ingredient rather than a standalone active. It’s not a hero ingredient. It’s a supporting player.

Where Most Brands Get This Wrong #

Concentration is the most common mistake. Brands see “resveratrol 1%” on a competitor’s label and brief us to match it. At 1% trans-resveratrol in an aqueous serum, you have a solubility problem before you have a stability problem. The practical stable concentration in a water-based formula without solubilizers is closer to 0.3–0.5%. Getting to 1% requires either a high-solubilizer load (which affects skin feel and can cause compatibility issues with other actives) or encapsulation (which, as noted, roughly triples the raw material cost for that ingredient).

Encapsulation sounds great until you price it. For resveratrol specifically, encapsulated grades run approximately 3× the cost of standard trans-resveratrol powder. At MOQ 1000 units, that cost difference is often $0.60–$1.20 per unit — significant for an indie brand at early stage. We have that conversation upfront now. We didn’t always, and it caused problems mid-project.

The other mistake: assuming that “natural” antioxidants are inherently stable. EGCG comes from green tea. It is also one of the most oxidation-prone cosmetic actives we work with. The natural origin doesn’t confer stability. If anything, the complex matrix of a botanical extract introduces more variability than a synthetic active — batch-to-batch variation in polyphenol content, variable trace metal loads, inconsistent pH. We now require certificate of analysis with polyphenol assay and metal content for every EGCG raw material lot. That requirement came from a specific batch failure, not from theory.

Worked fine at 200g lab scale. At 150kg production, the EGCG serum showed visible browning at week 6 of PCT. Root cause: the production-scale water system had higher dissolved oxygen than our lab purified water, and the larger batch volume meant longer exposure time during mixing. We now purge the water phase with nitrogen before EGCG addition on every production run. It’s not a perfect solution.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask.

If you’re targeting EU with an antioxidant positioning, the regulatory path is clean for all three actives at standard use levels, but the claims landscape is strict — “anti-aging” claims require substantiation under EU Cosmetics Regulation 1223/2009, and we’ll need to align on what’s supportable before we finalize the formula. If you’re targeting the US market with a clean beauty positioning, the preservative system becomes a secondary conversation — low-pH polyphenol formulas can be self-preserving in some formats, but we don’t rely on that without challenge testing data.

For a single-active EGCG serum, our standard starting point is 1.0–1.5% EGCG in a low-water gel base, pH 5.0, with 0.1% EDTA, nitrogen-purged processing, and opaque airless packaging. That format gives us reliable 12-month stability at 25°C. For a resveratrol-focused formula, we typically work in an anhydrous or low-water serum-oil hybrid — it sidesteps the solubility issue and the photoisomerization risk is manageable with opaque packaging.

Multi-active combinations: we’ll always run a compatibility screen before committing to a formula. That’s a 4-week preliminary test, not a full stability run. It adds time to the project timeline, but it’s cheaper than a failed 12-week stability study.

MOQ for these formats typically starts at 500kg bulk, which translates to roughly 5,000–10,000 units depending on fill weight. Airless pump packaging adds $0.40–$0.80 per unit at that MOQ. Worth building into your cost model early.

Frequently Asked Questions #

Q: We want to put “resveratrol 1%” on the label — is that actually achievable in a stable formula?

In a standard aqueous serum, not really. Solubility caps out around 0.3–0.5% without aggressive solubilizer systems. If 1% is a marketing requirement, we’d look at an anhydrous format or encapsulated resveratrol — but budget for roughly 3× the raw material cost on that ingredient.

Q: Can we combine EGCG and vitamin C in the same formula?

It’s technically possible but the pH windows conflict. L-ascorbic acid needs pH 2.5–3.5; EGCG is most stable at pH 4.0–6.0. You can compromise at pH 3.5–4.0, but both actives are operating outside their optimal range. In most projects we’ve run, the 12-week stability results are marginal. Encapsulation of one active is the cleaner solution.

Q: How do we know if our EGCG raw material is good quality?

Ask for a certificate of analysis showing polyphenol assay (we want EGCG content above 45% of total polyphenols), iron content below 1 ppm, and copper below 0.5 ppm. If the supplier can’t provide metal content data, that’s a red flag. Batch-to-batch variation in unspecified botanical extracts is one of the most common root causes of stability failures we see.

Q: What’s the minimum effective concentration for quercetin in a topical formula?

Honestly, the topical efficacy data for quercetin as a standalone active is thin. We typically use it at 0.2–0.3% as a synergistic antioxidant alongside a primary active. If you want to lead with quercetin on-pack, we’d want to discuss what claim you’re supporting — the evidence base for specific concentrations is not as strong as for EGCG or even resveratrol.

Q: Do we need airless packaging for all three actives?

For EGCG, yes — oxygen exposure is the primary degradation driver and airless packaging is non-negotiable in our stability protocols. For resveratrol, opaque packaging is the priority (UV protection), and airless is preferred but not always required depending on the formula matrix. For quercetin in an anhydrous format, standard opaque packaging is usually sufficient. The packaging decision should follow the stability data, not the other way around.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.